Zafgen to Present at the 31st Annual ROTH Conference
13 Março 2019 - 6:00PM
Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical
company leveraging its proprietary knowledge of MetAP2 systems
biology to develop novel therapies for patients affected by a range
of metabolic diseases, announced today that Jeffrey Hatfield, Chief
Executive Officer of Zafgen, Inc. will participate in a fireside
discussion at the 31st Annual ROTH Conference on Tuesday, March 19,
2019 at 11:30 a.m. PT.
A live audio webcast and replay of the presentation will be
available through the Events and Presentations page of the
Investors section of the Company's website (www.zafgen.com) for 90
days following the conclusion of the live event.
About Zafgen
Zafgen (Nasdaq:ZFGN) is a clinical-stage biopharmaceutical
company leveraging its proprietary MetAP2 biology platform to
develop novel therapies for patients affected by complex metabolic
diseases. Zafgen has pioneered the study of MetAP2 inhibitors in
both common and rare metabolic disorders and is currently advancing
programs for type 2 diabetes, Prader-Willi syndrome and liver
diseases. Learn more at www.zafgen.com.
Media/Investor Relations Contacts:Zafgen, Inc.
Patricia Allen Chief Financial Officer 617-648-9792
MediaKrystle GibbsTen Bridge
Communicationskrystle@tenbridgecommunications.com 508-479-6358
InvestorsJohn
WoolfordWestwickejohn.woolford@westwicke.com443-213-0506
Zafgen (NASDAQ:ZFGN)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Zafgen (NASDAQ:ZFGN)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
Notícias em tempo-real sobre Zafgen Inc da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de